Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System
This study conducted a comprehensive evaluation of the real-world safety of Tepotinib. The study validates clinical assertions about Tepotinib's safety profile and identifies its novel signals, and also emphasized early monitoring of treatment. Our findings will better guide the clinical practice of Tepotinib and provide a basis for larger prospective studies in the future.
Authors
- Wei Su (ORCID: https://orcid.org/0000-0002-6017-8543)
- Zhang Li-xi (ORCID: https://orcid.org/0000-0002-3699-1585)
- Cuiping Liu (ORCID: https://orcid.org/0000-0002-7383-1505)
- Xu Qi (ORCID: https://orcid.org/0000-0002-8381-8515)
Institutions
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1371/journal.pone.0339005
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00